CN115996949A - 犬抗体变异体 - Google Patents

犬抗体变异体 Download PDF

Info

Publication number
CN115996949A
CN115996949A CN202180028973.4A CN202180028973A CN115996949A CN 115996949 A CN115996949 A CN 115996949A CN 202180028973 A CN202180028973 A CN 202180028973A CN 115996949 A CN115996949 A CN 115996949A
Authority
CN
China
Prior art keywords
igg
antibody
constant domain
canine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028973.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·伯杰龙
H·L·坎波斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CN115996949A publication Critical patent/CN115996949A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180028973.4A 2020-04-17 2021-04-16 犬抗体变异体 Pending CN115996949A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17
US63/011,453 2020-04-17
PCT/US2021/027836 WO2021212081A1 (en) 2020-04-17 2021-04-16 Canine antibody variants

Publications (1)

Publication Number Publication Date
CN115996949A true CN115996949A (zh) 2023-04-21

Family

ID=75888187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028973.4A Pending CN115996949A (zh) 2020-04-17 2021-04-16 犬抗体变异体

Country Status (17)

Country Link
US (1) US20230242635A1 (https=)
EP (1) EP4136106A1 (https=)
JP (1) JP2023522029A (https=)
KR (1) KR20230005156A (https=)
CN (1) CN115996949A (https=)
AU (1) AU2021256056A1 (https=)
BR (1) BR112022020944A2 (https=)
CA (1) CA3175921A1 (https=)
CL (2) CL2022002857A1 (https=)
CO (1) CO2022014695A2 (https=)
EC (1) ECSP22080846A (https=)
IL (1) IL297287A (https=)
MX (1) MX2022012866A (https=)
PE (1) PE20230108A1 (https=)
PH (1) PH12022552742A1 (https=)
TW (1) TW202204403A (https=)
WO (1) WO2021212081A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN120590527A (zh) 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
MX2023003624A (es) 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.
AU2023289332A1 (en) * 2022-06-21 2024-12-12 Zoetis Services Llc Canine antibody mutants
JP2026508096A (ja) 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521461A (ja) * 2012-06-06 2015-07-30 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
CN107296955A (zh) * 2011-02-04 2017-10-27 硕腾服务有限责任公司 免疫原性支气管炎博德特氏菌组合物
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR102605798B1 (ko) * 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
UA120981C2 (uk) * 2015-09-18 2020-03-10 Чугаі Сейяку Кабусікі Кайся Антитіло, що зв'язується з il-8, та його застосування
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3494991A4 (en) * 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN113544153B (zh) * 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
MX2023003624A (es) * 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.
EP4284825A2 (en) * 2021-01-28 2023-12-06 Zoetis Services LLC Mutations in canine antibody constant regions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107296955A (zh) * 2011-02-04 2017-10-27 硕腾服务有限责任公司 免疫原性支气管炎博德特氏菌组合物
JP2015521461A (ja) * 2012-06-06 2015-07-30 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEE M. NG 等: "Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 51, 23 January 2014 (2014-01-23), pages 51 - 58, XP028772607, DOI: 10.1016/j.ejps.2013.08.033 *
TANG, L等: "immunoglobulin gamma heavy chain B [Canis lupus familiaris]", GENBANK: AAL35302.1, 26 November 2001 (2001-11-26), pages 1 *

Also Published As

Publication number Publication date
ECSP22080846A (es) 2023-02-28
MX2022012866A (es) 2022-11-08
IL297287A (en) 2022-12-01
US20230242635A1 (en) 2023-08-03
WO2021212081A1 (en) 2021-10-21
KR20230005156A (ko) 2023-01-09
CL2023003377A1 (es) 2024-04-19
PE20230108A1 (es) 2023-01-25
CO2022014695A2 (es) 2022-10-21
BR112022020944A2 (pt) 2022-12-27
TW202204403A (zh) 2022-02-01
CA3175921A1 (en) 2021-10-21
JP2023522029A (ja) 2023-05-26
PH12022552742A1 (en) 2024-03-25
EP4136106A1 (en) 2023-02-22
AU2021256056A1 (en) 2022-10-20
CL2022002857A1 (es) 2023-06-02

Similar Documents

Publication Publication Date Title
CN115996949A (zh) 犬抗体变异体
US20250026834A1 (en) Feline antibody variants
US12612454B2 (en) Canine antibody variants
EP4263596A1 (en) Mutations in feline antibody constant regions
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação
BR122024007417A2 (pt) Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination